12h agoThe FlyBULLISH 63Product/PR
Archived explainer. For the current picture see today's RVTY page.
Why Is REVVITY INC (RVTY) Stock Up Today?
By the Top Tier Newswire AI Desk · September 24, 2026 at 3:27 PM ET · reviewed against 3 wire stories
REVVITY INC (RVTY) is up +6.55% in the latest session. Our newswire has captured 3 stories on RVTY across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 61/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Revvity Inc (RVTY) shares rose 6.55% to $151.42 on Tuesday, driven by the company’s announcement of a new diagnostic product. The stock opened near $141.81 and climbed steadily through the session, hitting a high of $151.47 at 3:25 PM ET. The move followed the launch of a CE-IVDR-certified kit for early detection of Type 1 Diabetes, which is now available in Europe.
What Happened
Revvity announced the launch of its GSP T1D 3plex kit, a diagnostic tool designed for early detection of Type 1 Diabetes. The kit uses dried blood spots on the company’s newborn-screening instrument and is CE-IVDR certified, allowing its use in European markets. The product is not yet FDA-cleared for use in the United States. This product expansion highlights Revvity’s focus on diagnostic innovation and its growing presence in the global healthcare market. The announcement was covered in multiple reports, including The Fly and StockTitan, which emphasized the potential impact of the new offering on the company’s revenue streams.
What The Data Shows
The stock’s intraday performance showed strong momentum, with volume reaching 0.9 million shares, or 0.6 times the 3-month daily average. The session high of $151.47 marked a new 52-week high for the stock, which has traded between $81.22 and $149.52 over the past year. The company’s fundamentals include a market cap of $16.0 billion, a P/E ratio of 67.3, and trailing 12-month revenue growth of 4.1%. Recent insider transactions show three sales totaling $1.3 million over the past 90 days, with no insider purchases reported. Meanwhile, former President Donald J. Trump disclosed a purchase of $50,001 to $100,000 in RVTY stock on March 18.
What To Watch
Investors should continue to monitor Revvity’s product pipeline and regulatory developments, particularly any progress toward FDA clearance for the GSP T1D 3plex kit in the U.S. Additionally, the company’s next earnings report and broader coverage from analysts will provide further insight into its market performance.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
RVTY by the numbers
Last: $151.42Session: +6.55%Coverage: 3 stories / 3 sourcesAI sentiment: 61/100 (bullish)Mkt cap: $16.0BP/E: 67.352w: $81.22 to $149.52
The headlines behind the move
13h agoStockTitanBULLISH 63Product/PR
Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
The CE-IVDR-certified kit uses dried blood spots on Revvity’s newborn-screening instrument and will initially be available in Europe; it is not FDA-cleared.
1d agoBarchartBULLISH 56General
Is Revvity Stock Outperforming the Dow?
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on RVTY: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier RVTY move explainers: 2026-09-24 · 2026-09-16 · 2026-09-15